By Padmanabhan Ananthan
March 9 (Reuters) – U.S. drugmaker Pfizer said on Monday its experimental drug for a chronic skin disease met the main goal in a mid-stage study.
Here are some details:
(Reporting by Padmanabhan Ananthan in Bengaluru; Editing by Mrigank Dhaniwala)





Comments